Participant flow

Radiation Therapy and Cetuximab in Treating Patients With Recurrent Head and Neck Cancer · Source last updated 2016-04-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   All patients enrolled will receive cetuximab 400 mg/m 2 IV x 1 dose 1 week prior to delivery of SBRT. Patients will then receive 15 Gy x 1 using SBRT and cetuximab i.v. 250 mg/m2 weekly for 4 weeks (total of 5 doses at 250 mg/m2).

   id

   FG000

   title

   Biological/Vaccine: Cetuximab

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Death

   2. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Adverse Event

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         2

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         2

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice